A Phase 1 interventional study of [11C]DPA-713 in Schizophrenia and Bipolar Disorder, sponsored by Johns Hopkins University. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-10.
Sponsored by Johns Hopkins University · Phase 1, Interventional, and Diagnostic
Many neurological diseases, including AIDS dementia, Alzheimer's disease and schizophrenia, involve an inflammatory component thought to specifically involve glial cell activation. The Investigators has been concerned with the development of tools for noninvasive imaging of inflammatory processes in psychotic disease. Here, the investigators aim to use PET-based neuroimaging with carbon-11 N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide, ([11C]DPA)-713 to quantify regional distribution of translocator protein (TSPO), a putative marker of inflammation, in the brains of patients with schizophrenia and bipolar disorder, type I. The investigators will focus on patients in the early stages of disease (within first five years of onset of schizophrenia diagnosis and within first five years of first manis, respectively) to minimize the confounds of age-, chronic illness-, and medication- effects on our results.
Exclusion Criteria:
Patients with Schizophrenia Disorder will be imaged with \[11C\] DPA-713
Drug: [11C]DPA-713
Patients with Bipolar Disorder will be imaged with \[11C\] DPA-713
Drug: [11C]DPA-713
Normal volunteers will be imaged with \[11C\] DPA-713
Drug: [11C]DPA-713
\[11C\]DPA-713 PET imaging
Sensitivity and Specificity of ([11C]DPA)-713 PET brain imaging in patients with recent onset schizophrenia and in patients with recent onset of mania
To determine regional brain uptake of this radioligand in patients with recent onset schizophrenia and in patients with recent onset of mania
Time frame: within five years of onset of schizophrenia or within five years of first manic episode
PET Imaging of microglial activation
To evaluate changes in activation of microglia in patients with acute schizophrenia and bipolar disorder relative to controls
Time frame: 5 years
This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins University